Total medical devices industry private equity deals in Q4 2020 worth $3.03bn were announced globally, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

The value marked an increase of 7.4% over the previous quarter and a rise of 55.5% when compared with the last four-quarter average, which stood at $1.95bn.

Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $2.69bn. At the country level, the US topped the list in terms of deal value at $2.6bn.

In terms of volumes, North America emerged as the top region for medical devices industry private equity deals globally, followed by Europe and then Asia-Pacific.

The top country in terms of private equity deals activity in Q4 2020 was the US with 21 deals, followed by the UK with five and Canada with two.

In 2020, as of the end of Q4 2020, medical devices private equity deals worth $8.61bn were announced globally, marking an increase of 91.9% year on year.

Medical devices industry private equity deals in Q4 2020: Top deals

The top five medical devices industry private equity deals accounted for 83.4% of the overall value during Q4 2020.

The combined value of the top five medical devices private equity deals stood at $2.53bn, against the overall value of $3.03bn recorded for the quarter.

The top five medical devices industry deals of Q4 2020 tracked by GlobalData were:

1) Casdin Capital and Rock Springs Capital Management’s $869.2m private equity deal with Exact Sciences

2) The $700m private equity deal with Verily Life Sciences by Alphabet , Ontario Teachers Pension Plan, Silver Lake Partners and Temasek Holdings (Private)

3) JR Dallas Wealth Management’s $440m private equity deal with Vivera Pharmaceuticals

4) The $286.77m private equity deal with Bioneb by GEM Global YieldSCS

5) ClearBridge Investments , Coatue Management , First Light Asset Management, Highland Capital Partners , Millennium Management , Neuberger Berman Wealth Management , Orbimed Advisors, TPG Sixth Street Partners and T Rowe Price Associates ‘ private equity deal with Caris Life Sciences for $235m.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.